XM does not provide services to residents of the United States of America.
E
E

EastmanChemical

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. Carnival, FedEx, Micron Technology

U.S. RESEARCH ROUNDUP-Carnival, FedEx, Micron Technology June 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Carnival, FedEx and Micron Technology, on Thursday. HIGHLIGHTS * Carnival Corp CCL.N : Macquarie raises target price to $25 from $24 * FedEx Corp FDX.N : Daiwa Capital Markets raises target price to $318 from $296 * Micron Technology Inc MU.O : JP Morgan raises target price to $180 from $130 * Unifirst Cor
A
E
G
H
H
M
N
S
A
C
C
E

Eastman Chemical Co Files For Mixed Shelf Offering, Size Not Disclosed - SEC Filing

BRIEF-Eastman Chemical Co Files For Mixed Shelf Offering, Size Not Disclosed - SEC Filing Eastman Chemical Co EMN.N : EASTMAN CHEMICAL CO FILES FOR MIXED SHELF OFFERING, SIZE NOT DISCLOSED - SEC FILING Source text for Eikon: [ID:n0001193125-24-158349] Further company coverage: EMN.N
E

U.S. Analog Devices, Nvidia, Snowflake

U.S. RESEARCH ROUNDUP-Analog Devices, Nvidia, Snowflake May 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Analog Devices, Nvidia and Snowflake, on Thursday. HIGHLIGHTS * Analog Devices Inc ADI.O : Jefferies raises target price to $280 from $250 * Dycom Industries Inc DY.N : D.A.
A
H
N
T
A
D
G
E

U.S. AN2 Therapeutics, Ecolab, RPM International

U.S. RESEARCH ROUNDUP-AN2 Therapeutics, Ecolab, RPM International May 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AN2 Therapeutics, Ecolab and RPM International, on Thursday. HIGHLIGHTS * AN2 Therapeutics Inc ANTX.O : Evercore ISI cuts target price to $2 from $7 * Biolife Solutions Inc BLFS.O : Maxim Group raises target price to $30 from $25 * Ecolab Inc ECL.N : Evercore ISI raises target price to $250 from $1
C
A
D
E
A
C
E

U.S. Domino's Pizza, HCA Healthcare, WW Grainger

U.S. RESEARCH ROUNDUP-Domino's Pizza, HCA Healthcare, WW Grainger April 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Domino's Pizza, HCA Healthcare and WW Grainger, on Tuesday. HIGHLIGHTS * Domino's Pizza Inc DPZ.N : BTIG raises target price to $580 from $515 * HCA Healthcare Inc HCA.N : TD Cowen cuts target price to $360 from $371 * Molina Healthcare Inc MOH.N : TD Cowen cuts target price to $412 from $453 * W
A
C
C
X
O
A
H
W
E
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.